Previously, we developed CXCR4-ligand modified peptide NPs bearing anti-VEGFA siRNA and demonstrated efficient down-regulation of the gene expression and subsequent anti-angiogenic effects in vitro and in vivo in the EM model [18,23,24]. The gene discussed is VEGFA; the disease is erythema multiforme.